Trovagene Closes $15M Direct Offering; Adopts RainDance Digital PCR System | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Trovagene today said that it has closed on a registered direct offering of $15 million of its common stock to an institutional investor at $7 per share.

Separately, the company and RainDance Technologies said earlier in the week that Trovagene has adopted RainDance's RainDrop Digital PCR System for R&D work.

Net proceeds from its $15 million offering will be used for R&D activities, working capital, and general corporate purposes, Trovagene said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.